LE 135

LE 135

Application

LE 135 has been used for in vitro islet treatment.

Biochem/physiol Actions

LE135 is a retinoic acid receptor (RAR) antagonist with selectivity for RARβ (Ki = 220 nM) over RARα (Ki = 1.4 µM). LE135 inhibits retinoic acid-induced transcriptional activation of RARβ (>70% inhibition at 10 µM), but not RARα, RARγ or retinoid X receptor α (RXRα). There is high interest in retinoic acid receptors for cancer and for differentiation studies. LE135 has been shown to inhibit retinoid Am80-induced differentiation of human promyelocytic leukemia HL-60 cells with an IC50 value of 0.2 µM. LE135 has been used to study the role of a retinoic acid receptor-β (RARβ) on the differentiation of mesenchymal stem cells, and was found to inhibit the neuronal differentiation promoting effects of all-trans retinoic acid (ATRA) on mesenchymal stem cells.

Features and Benefits

This compound is featured on the Nuclear Receptors (Non-Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Packaging

5, 25 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level Manufacturer Storage Temp. Solubility Form Assay Price Quantity
3574134 LE 135 yellow to orange 100 SIGMA-ALDRICH 2-8°C DMSO: 15 mg/mL, clear powder ≥98% (HPLC)
£554.36 (exc VAT) per 25MG
-
+
3574135 LE 135 yellow to orange 100 SIGMA-ALDRICH 2-8°C DMSO: 15 mg/mL, clear powder ≥98% (HPLC)
£136.50 (exc VAT) per 5MG
-
+